Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine


  • Of Dendreon And Pfizer Shorts Friday, 17 Apr 2009 | 10:29 AM ET

    Not a surprise, but my post yesterday on what one reader called the analyst "flip-flop" on Dendreon generated a lot of responses and queries.

  • Analyst Eats Dendreon Crow Friday, 17 Apr 2009 | 9:51 AM ET

    As late as the day before the positive Dendreon data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients. Today he's offering a bit of a mea culpa.

  • A Tweet Tip On Roche-Genentech Wednesday, 15 Apr 2009 | 10:55 AM ET

    In my less than five weeks on Twitter, I've gotten ideas for four blogs and late yesterday, for the first time, I got a legit news tip off a tweet (for the uninitiated, that's what the short messages sent on Twitter are called.)

  • Pfizer Gets Its Irish Up Tuesday, 14 Apr 2009 | 11:46 AM ET

    Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.

  • What's Up With Dendreon? Monday, 13 Apr 2009 | 11:43 AM ET

    Dendreon is up yet again today on heavy volume. Several investors have emailed me and one analyst voicemailed me asking if I know what's going on. I don't. And I see no news.

  • The Beat Goes On With Merck & Cardiome Thursday, 9 Apr 2009 | 8:48 AM ET

    Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.

  • Eli Lilly Drops The F In The UK Wednesday, 8 Apr 2009 | 9:00 AM ET

    Drug names are a favorite topic of mine. So, can someone please explain why the proposed commercial name for Eli Lilly's new bloodthinner in the U.S. is "Effient" with two f's, but in the UK, where the pill is making its debut today, it's going by "Efient" with only one f?

  • "Your" Views From 30,000 Feet Tuesday, 7 Apr 2009 | 9:29 AM ET

    The emails flew over my post yesterday about the big pharma slides I saw on a flight last week.

  • China Makes Bold Move on Volatile Health Care Issue Monday, 6 Apr 2009 | 2:17 PM ET

    China announced Monday the outlines of a thorough reform of the health care system that pledges to provide improved services to all citizens by 2020, tackling a critical issue that has become a major source of public dissatisfaction.

  • Big Pharma At 30,000 Feet Monday, 6 Apr 2009 | 8:58 AM ET

    I don't want to get anyone in trouble, so I won't name the company, the drug or even what it's for. (Note to corporate PR folks reading this: Don't even try to pry it out of me. My lips are sealed.) All I'll say is that it's one of the biggies.

  • Dendreon's Freaky Friday Friday, 3 Apr 2009 | 4:08 PM ET

    I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon story.

  • It's Diabetes Drug Days Wednesday, 1 Apr 2009 | 11:28 AM ET

    An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.

  • Top Doctors Take Stand Against Pharma Marketing 'Swag' Tuesday, 31 Mar 2009 | 4:02 PM ET

    A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.

  • Lilly & Amylin: Please Keep It Simple Tuesday, 31 Mar 2009 | 12:46 PM ET

    Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.

  • Novartis Drug Approved as Kidney Cancer Treatment Monday, 30 Mar 2009 | 6:09 PM ET

    A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.

  • Knocked Out Of The Arena Monday, 30 Mar 2009 | 11:27 AM ET

    There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.

  • Genentech, Dendreon & Your Emails Friday, 27 Mar 2009 | 4:24 PM ET

    I'm on the road on assignment, but used a little downtime to go through the "Pharma's Market" mailbox. Regarding my farewell to Genentech post yesterday a couple of folks emailed to point out that GENE was Genentech's ticker symbol when it was traded on the Nasdaq back in the day. Then it was GNE on the NYSE before going to the much better DNA.

  • Goodbye Genentech & Your DNA Thursday, 26 Mar 2009 | 2:29 PM ET

    DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.

  • Did Dendreon Do Itself In? Wednesday, 25 Mar 2009 | 12:34 PM ET

    Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.

  • Roll Out The Red Carpet! ASCO Goes Hollywood Tuesday, 24 Mar 2009 | 10:45 AM ET

    All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.